REFRACTORY MELANOMA
Clinical trials for REFRACTORY MELANOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY MELANOMA trials appear
Sign up with your email to follow new studies for REFRACTORY MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Two-Drug combo aims to starve and attack advanced cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:44 UTC
-
Last-Resort drug offered to melanoma patients
Disease control NO_LONGER_AVAILABLEThis program gives patients with advanced melanoma that hasn't responded to standard treatments access to an experimental drug called vidutolimod. The goal is to provide a potential treatment option when no others are available. The study is no longer enrolling participants.
Matched conditions: REFRACTORY MELANOMA
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
New combo tackles tough melanoma
Disease control OngoingThis study tests whether adding a drug called rigosertib to the immunotherapy pembrolizumab can help shrink or control advanced melanoma that has stopped responding to standard immunotherapy. About 7 adults with melanoma that cannot be surgically removed or has spread will receiv…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated May 22, 2026 14:03 UTC
-
Targeted drug tipifarnib tested in kids with rare HRAS-Driven cancers
Disease control OngoingThis study tests the drug tipifarnib in children and young adults (ages 1 to 21) whose advanced solid tumors, lymphoma, or related cancers have a specific change in the HRAS gene. The goal is to see if tipifarnib can shrink or stop the growth of these hard-to-treat cancers. Parti…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
New drug cocktail shows promise for deadly brain tumors in melanoma patients
Disease control OngoingThis study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. The drugs work by blocking tumor growth and helping the immune system attack cancer cells. The trial involves 29 adults with untreated brain metastases and aims to s…
Matched conditions: REFRACTORY MELANOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 18, 2026 12:07 UTC